 |
The DDR: Editorial board
|
|
|
|
|
|
|
|
|
|
|
 |
Brooks Adams BA, MBA, Strategic Project Planning, Philip Morris USA
Brooks Adams has recently transitioned within Philip Morris USA into Strategic Product Planning. He was previously responsible for directing the commercialisation plans for Chrysalis' proprietary pulmonary drug delivery aerosol technology.
Prior to joining Chrysalis, Brooks worked in business development, sales and marketing roles in biotechnology and genomics. He is skilled in
evaluating growth opportunities; strategic marketing and consultative platform selling; and leading new product launches.
Brooks received an MBA from the Fuqua School of Business, Duke University, and a B.A. from Davidson College. He is also a Chartered Financial
Analyst.
|
 |
Dr Janet A Halliday BSc, MRPharmS, PhD, Research and Development Director, Controlled Therapeutics Ltd
Dr Halliday joined CT as a bench formulation scientist initially working on solid dosage forms before working on Cervidil. Janet was
involved in FDA audits and partnership visits with Forest, Ferring and Zeneca. She has since worked on development projects both in
partnership with other companies (Fisons, PowderJect, Britannia) and on CT-led hydrogel projects. Dr Halliday is now responsible for
directing work leading to new IP on transmucosal delivery, new polymers and new loading approaches as well as being involved in examining
both in- and out-licensing opportunities. Janet is currently an elected member of RPSGB Industrial Pharmacist Group committee and a member
of Academy of Pharmaceutical Sciences and Controlled Release Society.
|
 |
Michael Hite, Senior Formulator & Technical Writer, SCOLR Pharma, Inc.
Michael joined SCOLR Pharma in 2000 as a formulator and is one of the founding members of the Company's product development
group. He is a graduate of Amherst College and is a member of the American Association of Pharmaceutical Scientists (AAPS), the
Controlled Release Society (CRS), and the American Chemical Society (ACS). Michael has published multiple articles in
peer-reviewed journals, presented numerous poster presentations at the AAPS and CRS national conferences, and is a frequent
editorial contributor to numerous pharmaceutical industry publications.
|
 |
Ravi Kiron, PhD, MBA, Executive Director, New Technology Assessment & Planning, Alza Corporation (a division of Johnson & Johnson)
Dr Ravi Kiron recently joined Alza Corporation as an Executive Director for New Technology Assessment and Planning. He will be a member of
Alza's Executive Committee. Dr Kiron is an experienced pharmaceutical industry scientist and strategic analyst with significant experience in management, leadership and
problem solving. He has diverse experience and a broad perspective of the various processes of pharmaceutical drug discovery, pre-clinical
and early clinical drug development, project management, external technology investments and analysis, Mergers & Acquisitions, compound
request management, database development and information protection and planning, knowledge and alliance management including in- and
out-licensing for drug discovery and information technology needs.
|
 |
Richard Korsmeyer, Director, Technology Assessment, Pfizer Global Research & Development
Richard Korsmeyer initially worked on the development of oral drug delivery technology at Pfizer before taking a management role
as leader of the Oral Controlled Release Group. In his current role, he is responsible for managing a group that systematically
evaluates technology for potential applicability to drug development, and works with technology companies to put agreements in
place and to manage joint development projects. He is also responsible for supporting evaluations of product licensing
opportunities and due diligence evaluations. He has published in serveral areas, including drug delivery, and holds a number of
patents. His current professional associations include the American Association of Pharmaceutical Scientists and the Controlled
Release Society. He received his MS and PhD in Chemical Engineering from Purdue University.
|
 |
Philip Brown, PhD, MBA, Commercial Analyst, Vectura Group plc
Philip joined Vectura in December 2005. Philip works within the commercial and business development team undertaking research and analysis to support strategic decisions for Vectura. From 2001 to 2005 Philip worked in PharmaVentures consultancy where he was involved in a number of client-based consultancy projects involving
aspects of strategy development, technical and commercial due diligence and licensing for drug delivery, biotech and
pharmaceutical companies. He has published a number of articles relating to scientific reseach. Further publications include a
review, book chapter and a textbook aimed at university students. He is also a regular contributor to the DDR and PharmaDeals
Review.
|
|
Steven Sanders PhD, Vice President, R&D, Aveva DDS, Inc.
Dr Steven Sanders leads the development of Aveva DDS' pipeline of transdermal products. His 20+ years of experience in clinical research and specialty product development contributes to Aveva's ability to leverage the technology available from their parent company, Nitto Denko, as well as providing synergistic support for partner companies in their efforts for improved drug delivery. Dr. Sander's interests center on maximizing therapeutic effectiveness of drug compounds by applying innovative drug delivery technologies
|
 |
Drew Hannaman, Vice President of Research & Development, Ichor Medical Systems
Drew Hannaman is a co-inventor of the TriGrid(TM) electroporation technology and, during his seven years as the Vice President of Research & Development for Ichor Medical Systems, has been responsible for guiding development of the TriGrid Delivery System for intramuscular delivery (TDS-IM).
|
|
|
|
|
|
|
